Avenzo Therapeutics announces first patient dosed in Phase 1/2 clinical study of AVZO-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate

CAR-T Digest - August 2020

Weekly Digest - July 2025

08 July 2025: Avenzo Therapeutics announces first patient dosed in Phase 1/2 clinical study of AVZO-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate

Avenzo Therapeutics has dosed the first patient in a Phase 1/2 clinical trial of AVZO-1418, an EGFR/HER3 bispecific antibody-drug conjugate, for advanced solid tumors
The trial will assess safety, tolerability, and preliminary activity of AVZO-1418 both as monotherapy and in combination
AVZO-1418 targets tumors with EGFR and HER3 co-expression and aims to improve selectivity and therapeutic effect across multiple tumor types